Myriad Genetics
MYGN
250 hedge funds and large institutions have $2.56B invested in Myriad Genetics in 2017 Q4 according to their latest regulatory filings, with 55 funds opening new positions, 89 increasing their positions, 78 reducing their positions, and 23 closing their positions.
139% more first-time investments, than exits
New positions opened: 55 | Existing positions closed: 23
40% more call options, than puts
Call options by funds: $7.66M | Put options by funds: $5.46M
14% more repeat investments, than reductions
Existing positions increased: 89 | Existing positions reduced: 78
14% more funds holding
Funds holding: 220 → 250 (+30)
2.14% less ownership
Funds ownership: 109.98% → 107.84% (-2.1%)
6% less capital invested
Capital invested by funds: $2.72B → $2.56B (-$158M)
67% less funds holding in top 10
Funds holding in top 10: 6 → 2 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$30.3M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$29.1M |
| 3 |
Allianz Asset Management
Munich,
Germany
|
+$16M |
| 4 |
State Street
Boston,
Massachusetts
|
+$12.7M |
| 5 |
Canada Pension Plan Investment Board
Toronto Ontario,
Ontario, Canada
|
+$12.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$71.4M |
| 2 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
-$24.6M |
| 3 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$16.9M |
| 4 |
CM
Castleark Management
Chicago,
Illinois
|
-$14.3M |
| 5 |
Millennium Management
New York
|
-$11M |
MYGN Hedge Fund Activity: Q4 2017 in Review
250 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Myriad Genetics (MYGN) for Q4 2017, worth a combined $2.56B — down 5.8% from $2.72B a quarter earlier.
Buyers outnumbered sellers: 55 funds opened new MYGN positions and 23 closed out — a net gain of 32 holders — while 89 added to existing stakes and 78 trimmed.
The largest buyer was Vanguard Group, adding an estimated $30.3M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $71.4M sold.
- 250 institutional investors held Myriad Genetics (MYGN) as of Q4 2017, up from 220 in Q3 2017.
- Funds reported $2.56B of Myriad Genetics stock for Q4 2017, down 5.8% quarter-over-quarter.
- 55 funds opened new Myriad Genetics positions in Q4 2017 and 23 closed out, a net change of +32 holders.
- The largest Myriad Genetics buyer in Q4 2017 was Vanguard Group, an estimated $30.3M added.
- The largest Myriad Genetics seller in Q4 2017 was Consonance Capital Management, an estimated $71.4M sold.
Based on aggregated 13F filings for Q4 2017.